Nkarta (NKTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The annual meeting will be held virtually on June 10, 2026, with voting on four key proposals, including director elections, auditor ratification, executive compensation, and the frequency of future say-on-pay votes.
Stockholders of record as of April 17, 2026, are eligible to vote, with instructions provided for online, phone, and mail voting.
The Board recommends voting for all director nominees, for auditor ratification, for executive compensation, and for annual say-on-pay votes.
Voting matters and shareholder proposals
Election of two Class III directors (Ali Behbahani and Zachary Scheiner) to serve until 2029.
Ratification of Ernst & Young LLP as independent auditor for 2026.
Advisory approval of named executive officer compensation.
Advisory vote on holding future say-on-pay votes annually.
Procedures for shareholder proposals and director nominations for the 2027 meeting are outlined.
Board of directors and corporate governance
The Board consists of eight directors divided into three classes with staggered terms.
Majority of directors are independent under Nasdaq standards; CEO is not independent.
Separate roles for CEO and Chairman; Dr. Behbahani serves as independent Chairman.
Four standing committees: Audit, Compensation, Nominating and Governance, and Science and Technology.
Board and committees held regular meetings in 2025, with high attendance.
Succession planning for executive leadership is periodically reviewed.
Latest events from Nkarta
- Key votes include director elections, auditor ratification, and executive pay approval.NKTX
Proxy filing23 Apr 2026 - Pivot to off-the-shelf CAR-NK therapy in autoimmune diseases, with broad trials and strong cash runway.NKTX
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Biotech seeks up to $350M for NK cell therapy pipeline, with $100M ATM via Stifel.NKTX
Registration filing25 Mar 2026 - Dose escalation advanced in clinical trials; cash runway extends into 2029.NKTX
Q4 202525 Mar 2026 - Focused on CD19 NK cell therapy for autoimmune disease, advancing toward pivotal trials and outpatient care.NKTX
Leerink Global Healthcare Conference 202610 Mar 2026 - Allogeneic NK cell therapy advances with strong safety, pivotal data expected this year.NKTX
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Allogeneic CAR NK therapy advances in autoimmune diseases, with key data expected in 2025.NKTX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Leading allogeneic NK cell trials in autoimmune disease, prioritizing safety and drug-free remission.NKTX
Stifel 2024 Healthcare Conference13 Jan 2026 - Robust, safe, off-the-shelf NK cell therapy targets I&I with key data expected in 2025.NKTX
7th Annual Evercore ISI HealthCONx Healthcare Conference11 Jan 2026